Neoadjuvant Chemotherapy as a Model of Care: Optimizing Treatment of Mexican Breast Cancer Patients

María del Mar García, Denisse Añorve, Brenda Carbajal, Diana Flores-Díaz, Flavia Morales-Vásquez, Georgina Garnica-Jaliffe, Gregorio Quintero-Beuló, Cynthia Villarreal- Garza, Brizio Moreno8, Consuelo Díaz, Mónica Sánchez, María de la Luz García Tinoco, Adela Poitevin, Carolina Blanco, Andrea Castro, Leticia Bornstein, Jesús Miguel García- Foncillas, Angélica Ávila, Christian Aguila and Claudia Arce-Salinas

Medical Oncology Service, International Oncology Center, Mexico Medical Affairs - Oncology, Roche Mexico, Mexico Oncology Service, General Ignacio Zaragoza Regional Hospital ISSSTE, Mexico Oncology Service, Institute of Breast Diseases, Mexico Department of Medical Oncology, National Cancer Institute, Mexico Breast Tumors Unit of the Oncology Service, Hospital General de Mexico “Dr. Eduardo Liceaga ", Mexico Department of Research and Breast Tumors, National Cancer Institute, Mexico Medical Oncology Service, ISSSTE Leon Guanajuato, Mexico Medical Oncology Service, Angeles Acoxpa Hospital, Mexico Medical Oncology Service of the Military Hospital for Women's Specialties and Neonatology, Mexico Medical Oncology Service, Oncology Hospital Siglo XXI, Mexican Social Security Institute, Mexico Radiotherapy Service, Southern Medical Foundation, Mexico Medical Oncology, ABC Medical Center, Mexico Medical Oncology Service, ISSSTEP, Mexico National Medical Center November 20 ISSSTE, Mexico Division of Translational Oncology, Oncohealth Institute, Spain

^*Correspondance to: Claudia Arce-Salinas 

 PDF  Full Text Review Article | Open Access

Abstract:

Neoadjuvant Chemotherapy (NACT) is the standard of care for locally advanced breast tumors and may be administered in some operable tumors, although its use has not been widely adopted in all settings. In Mexico, 52% of breast cancer patients receive NACT [1]. Many factors contribute to less use of NACT when compared to other countries, including the lack of assessment and treatment decision-making by a Multidisciplinary Team (MDT), unavailability of NACT therapeutics, and readiness of a complete histopathological report. The aim of this review is to describe prognostic factors and provide evidence-based recommendations for both the optimal use of NACT and collaborative treatment decision making in our local setting to improve patient outcomes.

Keywords:

Breast cancer; LABC; Neoadjuvant chemotherapy; Multidisciplinary teams

Cite the Article:

del Mar García M, Añorve D, Carbajal B, Flores-Díaz D, Morales-Vásquez F, Garnica-Jaliffe G, et al. Neoadjuvant Chemotherapy as a Model of Care: Optimizing Treatment of Mexican Breast Cancer Patients. Clin Oncol. 2020; 5: 1728.